WO2018014799A1 - 重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂 - Google Patents

重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂 Download PDF

Info

Publication number
WO2018014799A1
WO2018014799A1 PCT/CN2017/093088 CN2017093088W WO2018014799A1 WO 2018014799 A1 WO2018014799 A1 WO 2018014799A1 CN 2017093088 W CN2017093088 W CN 2017093088W WO 2018014799 A1 WO2018014799 A1 WO 2018014799A1
Authority
WO
WIPO (PCT)
Prior art keywords
amplification
protein
ecoli
concentration
recombinase polymerase
Prior art date
Application number
PCT/CN2017/093088
Other languages
English (en)
French (fr)
Inventor
盛司潼
龚敬文
Original Assignee
广州康昕瑞基因健康科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州康昕瑞基因健康科技有限公司 filed Critical 广州康昕瑞基因健康科技有限公司
Publication of WO2018014799A1 publication Critical patent/WO2018014799A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Definitions

  • the present invention relates to a constant temperature amplification technique, and more particularly to a recombinant enzyme polymerase amplification (RPA) kit, an amplification method, and an amplification reagent.
  • RPA recombinant enzyme polymerase amplification
  • PCR polymerase chain reaction
  • Dissociate make it a single strand, so that it is combined with the primer to prepare for the next round reaction; (2) annealing the template DNA and the primer, and the template DNA is denatured into a single strand by heating, and the temperature is lowered to 55-60 ° C, The primer binds to the complementary sequence of the single strand of the template DNA; (3) the extension of the primer, the DNA template-primer conjugate under the action of DNA polymerase, at 70-75 ° C, using dNTP as the reaction raw material, the target sequence is The template, according to the principle of base pairing and semi-reserved replication, synthesizes a new semi-reserved replication strand complementary to the template DNA strand, and repeats the cyclic denaturation-annealing-extension process to obtain more "semi-reserved replication strands".
  • the object of the present invention is to provide a recombinase polymerase amplification kit, an amplification method and an amplification reagent, which can realize high-efficiency amplification of a specific nucleic acid sequence under constant temperature conditions, so that the process of nucleic acid amplification can be directly performed without PCR.
  • the instrument is completed under the conditions of a temperature cycling instrument.
  • the present invention provides a recombinase polymerase amplification kit comprising the following components: Ecoli RecA protein, lambdaphage Orf protein, Ecoli SSB protein, and DNA polymerase.
  • the kit further comprises an amplification reaction buffer
  • the amplification reaction buffer comprises a Tris buffer
  • the amplification reaction buffer further comprises polyethylene glycol, dithiothreitol, creatine phosphate And one or more of creatine kinases.
  • the kit further comprises a magnesium ion preparation.
  • the invention also provides a recombinase polymerase amplification method, the method comprising the following steps:
  • A. Configuring a reaction system comprising: a template nucleic acid molecule, a primer set, an Ecoli RecA protein, a ⁇ phage Orf protein, an Ecoli SSB protein, a DNA polymerase, dNTP, ATP, and an amplification reaction buffer, the amplification reaction
  • the buffer includes Tris buffer;
  • the amplification reaction is carried out at 20 to 65 °C.
  • the amplification reaction buffer further comprises one or more of polyethylene glycol, dithiothreitol, creatine phosphate and creatine kinase.
  • the primer set comprises a pair of primers having a length of 30 to 65 bp.
  • the Ecoli RecA protein concentration is 20 to 250 ng/ ⁇ L; the ⁇ phage Orf protein concentration is 20 to 80 ng/ ⁇ L; and the concentration of the Ecoli SSB protein is 200 to 1000 ng/ ⁇ L.
  • the invention also provides a recombinase polymerase amplification reagent comprising: Ecoli RecA protein, lambdaphage Orf protein, Ecoli SSB protein and DNA polymerase.
  • the amplification reagent further comprises an amplification reaction buffer
  • the amplification reaction buffer comprises a Tris buffer
  • the amplification reaction buffer further comprises polyethylene glycol, dithiothreitol, phosphoric acid muscle One or more of acid and creatine kinase.
  • the Ecoli RecA protein concentration is 20 to 250 ng/ ⁇ L; the Ecoli SSB protein concentration is 200 to 1000 ng/ ⁇ L; and the ⁇ phage Orf protein concentration is 20 to 80 ng/ ⁇ L.
  • the recombinase polymerase amplification kit of the invention expands the application range of recombinase polymerase amplification by using the synergistic amplification system of Ecoli RecA protein, Ecoli SSB protein and ⁇ phage Orf protein; compared with the conventional PCR technology,
  • the recombinase polymerase amplification reaction of the invention can be carried out under constant temperature conditions without a temperature cycle instrument such as a PCR instrument, and is not limited by the experimental space; the amplification reaction of the invention can be completed in 10 to 60 minutes, much faster than PCR technology or other isothermal amplification techniques.
  • Figure 1 is a diagram showing the agarose gel electrophoresis detection of recombinase polymerase amplification and control PCR amplification in the first embodiment.
  • Figure 2 is a capillary electrophoresis pattern of recombinase polymerase amplification in a second embodiment.
  • Figure 3 is a diagram showing the agarose gel electrophoresis detection of recombinase polymerase amplification in the third embodiment.
  • Figure 4 is a diagram showing the agarose gel electrophoresis detection of recombinase polymerase amplification in the fourth embodiment.
  • the present invention proposes a first embodiment, a recombinase polymerase amplification kit comprising the following components: Ecoli RecA protein, lambdaphage Orf protein, Ecoli SSB protein, and DNA polymerase.
  • the recombinase polymerase amplification of the present invention is a constant temperature amplification technique based on the principle of homologous recombination in vivo: at a suitable temperature, the recombinant enzyme Ecoli RecA protein and ⁇ phage Orf protein work together to form an enzyme with a primer. a complex with a primer that localizes to a homologous target sequence of a template nucleic acid molecule and forms a strand displacement; the single-stranded binding protein binds to the displaced nucleotide strand to prevent further substitution; and initiates DNA under the action of a DNA polymerase Chain synthesis, amplification of the target region on the template nucleic acid molecule.
  • the Ecoli RecA protein and the Ecoli SSB protein are derived from Escherichia coli, and the ⁇ phage Orf protein is derived from ⁇ phage.
  • the ⁇ phage Orf protein of the present invention is different from the species source of Ecoli RecA protein and Ecoli SSB protein, but can cooperate in the same system and realize recombinase polymerase amplification, thereby greatly expanding the application of recombinase polymerase amplification technology. range.
  • source refers only to its kind, not to the source of protein preparation.
  • the DNA polymerase is preferably a DNA polymerase having strand displacement activity at 20 to 65 °C.
  • the DNA polymerase is preferably Sau DNA polymerase, Bsu DNA polymerase or Bst DNA polymerase.
  • the kit further comprises dNTP, wherein the dNTP is an equimolar mixture of dTTP, dATP, dGTP and dCTP; the dNTP is used as a substrate for DNA strand synthesis during amplification. .
  • the kit further comprises ATP; during amplification, the ATP provides energy for a strand displacement process between the template nucleic acid molecule and the complex.
  • the kit further comprises an amplification reaction buffer, the amplification reaction buffer comprises a Tris buffer; and the Tris buffer is used to maintain the pH of the reaction system.
  • the amplification reaction buffer further comprises polyethylene glycol; after adding polyethylene glycol to the reaction system, polyethylene glycol is used as a high molecular substance, which occupies a large volume in the reaction system. In part, while repelling other components into the space, the other components in the amplification system are more fully contacted, thereby increasing the amplification efficiency.
  • the polyethylene glycol has an average molecular weight of 3,000 to 20,000; the polyethylene glycol in the molecular weight range is more repulsive to other components in the reaction system.
  • the amplification reaction buffer further comprises dithiothreitol; the dithiothreitol may have Effectively prevents the Ecoli RecA protein and DNA polymerase from being oxidized.
  • the amplification reaction buffer further comprises creatine phosphate and creatine kinase; the creatine phosphate and creatine kinase are used to catalyze ATP regeneration, and the process can be repeated continuously, thereby ensuring high efficiency. Amplification.
  • Tris buffer, polyethylene glycol, dithiothreitol, creatine phosphate and creatine kinase in the kit of the present invention can also be stored separately and mixed when the kit is used.
  • the kit further comprises a magnesium ion preparation for activating the DNA polymerase, thereby shortening the reaction time.
  • the magnesium ion preparation in the kit is stored separately from other components. During the use of the kit, the other components in the kit are thoroughly mixed, and then the magnesium ion preparation is added thereto to avoid non-specific amplification. .
  • the magnesium ion preparation is magnesium acetate or magnesium chloride.
  • the present invention proposes a second embodiment, a recombinase polymerase amplification method, comprising the following steps:
  • A. Configuring a reaction system comprising: a template nucleic acid molecule, a primer set, an Ecoli RecA protein, a ⁇ phage Orf protein, an Ecoli SSB protein, a DNA polymerase, dNTP, ATP, and an amplification reaction buffer, the amplification reaction
  • the buffer includes Tris buffer;
  • the amplification reaction is carried out at 20 to 65 °C.
  • the template nucleic acid molecule may be a double-stranded DNA molecule or a cDNA molecule synthesized by reverse transcription of RNA.
  • the Tris buffer of the present invention is used to maintain the pH of the reaction system, and the pH of the present embodiment ranges from 7.0 to 8.0.
  • the amplification reaction buffer further comprises polyethylene glycol; after adding polyethylene glycol to the reaction system, polyethylene glycol is used as a high molecular substance, which occupies a large volume in the reaction system. In part, while repelling other components into the space, the other components in the amplification system are more fully contacted, thereby increasing the amplification efficiency.
  • the polyethylene glycol has an average molecular weight of 3,000 to 20,000; the polyethylene glycol in the molecular weight range is more repulsive to other components in the reaction system.
  • the amplification reaction buffer further comprises dithiothreitol; the dithiothreitol can effectively prevent oxidation of the Ecoli RecA protein and the DNA polymerase in the mixture.
  • the amplification reaction buffer further comprises creatine phosphate and creatine kinase; the creatine phosphate and creatine kinase are used to catalyze ATP regeneration, and the process can be repeated continuously, thereby ensuring nucleic acid Efficient amplification of molecules.
  • the magnesium ion preparation is used to activate a DNA polymerase, thereby shortening the reaction time, and after the preparation of the reaction system, a magnesium ion preparation is added thereto to avoid non-specific amplification.
  • the magnesium ion preparation is magnesium acetate or magnesium chloride.
  • the template nucleic acid molecule is a double stranded DNA molecule.
  • human whole blood DNA is used as a template nucleic acid molecule.
  • the primer set comprises a pair of primers; the length of the primer is 30 to 65 bp, and the solution can ensure the specificity recognized during the chain replacement process.
  • actinRPA-0_F (SEQ ID NO: 1), actinRPA-0_R (SEQ ID NO: 2), actinRPA-1_F (SEQ ID NO: 3), actin RPA-1_R (SEQ ID NO: 4); actinRPA-2_F (SEQ ID NO: 5), actinRPA-2_R (SEQ ID NO: 6); or actinRPA-3_F (SEQ ID NO: 7), actinRPA-3_R (SEQ ID NO: 8) as primer set Recombinase polymerase amplification of the template nucleic acid molecule.
  • the DNA polymerase is a DNA polymerase having a strand displacement activity at 20 to 65 ° C
  • the DNA polymerase of the present scheme is applied to a recombinase polymerase amplification process to cause an amplification reaction. It can be carried out quickly at room temperature.
  • the DNA polymerase is Sau DNA polymerase, Bsu DNA polymerase or Bst DNA polymerase.
  • the concentration of the template nucleic acid molecule is from 10 pg/ ⁇ L to 100 ng/ ⁇ L; in the concentration range of the present embodiment, the amplification reaction of the template nucleic acid molecule can be performed efficiently.
  • the concentration of each primer in the primer set is 0.1 to 1.0 ⁇ M; in the concentration range of the present embodiment, the amplification reaction of the template nucleic acid molecule can be efficiently performed.
  • the Ecoli RecA protein concentration is 20 to 250 ng/ ⁇ L; the ⁇ phage Orf protein concentration is 20 to 80 ng/ ⁇ L; and the Ecoli SSB protein concentration is 200 to 1000 ng/ ⁇ L; Within the concentration range, the Ecoli RecA protein, the Ecoli SSB protein, and the ⁇ phage Orf protein are better synergistic, resulting in higher amplification efficiency.
  • the DNA polymerase concentration is 5 to 120 ng/ ⁇ L; in the concentration range of the present embodiment, the polymerization reaction of the template nucleic acid molecule can be performed efficiently.
  • the dNTP is an equimolar ratio mixture of dTTP, dATP, dGTP, and dCTP; the concentration of the dNTP is preferably 0.1 to 3 mM; and the dNTP is used as a substrate for polymerization to synthesize a DNA strand.
  • the concentration of the ATP is 1 to 10 mM; during amplification, the ATP provides energy for a strand displacement process between the template nucleic acid molecule and the complex, within the concentration range of the solution, It is beneficial to promote the progress of the amplification reaction.
  • the concentration of the Tris buffer is 20 to 500 mM; the pH of the solution ranges from 7.0 to 8.0; the present scheme facilitates the progress of the amplification reaction.
  • the concentration of the polyethylene glycol is 2.5 to 10 mM; in the concentration range of the solution, it is advantageous The progress of the amplification reaction.
  • the phosphocreatine concentration is 20 to 100 mM; the creatine kinase concentration is 10 to 1000 ng/ ⁇ L; and in the concentration range of the present embodiment, it is advantageous to promote regeneration of ATP.
  • the concentration of the dithiothreitol is 2.5 to 10 mM; in the concentration range of the present embodiment, it is advantageous to prevent oxidation of the Ecoli RecA protein and the DNA polymerase.
  • the concentration of the magnesium ion preparation in the reaction mixture is 5 to 30 mM; in the concentration range of the present embodiment, it is advantageous to activate the DNA polymerase action.
  • the present invention proposes a third embodiment, a recombinase polymerase amplification reagent comprising the following components: Ecoli RecA protein; lambdaphage Orf protein; Ecoli SSB protein; DNA polymerase.
  • the reagent further comprises dNTP; the dNTP is an equimolar mixture of dTTP, dATP, dGTP and dCTP, and the dNTP is used as a substrate for DNA strand synthesis.
  • the reagent further comprises ATP; the ATP provides energy for a strand displacement process between the template nucleic acid molecule and the complex.
  • the reagent further comprises an amplification reaction buffer
  • the amplification reaction buffer comprises a Tris buffer
  • the Tris buffer is used to maintain the pH of the reaction system, and the pH range of the embodiment At 7.0 to 8.0.
  • the amplification reaction buffer further comprises creatine phosphate and creatine kinase; the creatine phosphate and creatine kinase are used to catalyze ATP regeneration, and the process can be repeated continuously, thereby ensuring nucleic acid Efficient amplification of molecules.
  • the amplification reaction buffer further comprises polyethylene glycol; after adding polyethylene glycol to the reaction system, polyethylene glycol is used as a high molecular substance, which occupies a large volume in the reaction system. In part, while repelling other components into the space, the other components in the amplification system are more fully contacted, thereby increasing the amplification efficiency.
  • the polyethylene glycol has an average molecular weight of 3,000 to 20,000; the polyethylene glycol in the molecular weight range is more repulsive to other components in the reaction system.
  • the amplification reaction buffer further comprises dithiothreitol; the dithiothreitol is effective to prevent oxidation of Ecoli RecA and DNA polymerase.
  • the reagent further comprises a primer set, the primer set comprises a pair of primers; the primer has a length of 30 to 65 bp, and the solution can ensure the specificity recognized during the chain replacement process.
  • the Ecoli RecA protein concentration is 20 to 250 ng/ ⁇ L; the ⁇ phage Orf protein concentration is 20 to 80 ng/ ⁇ L; and the Ecoli SSB protein concentration is 200 to 1000 ng/ ⁇ L.
  • the DNA polymerase concentration is 5 to 120 ng/ ⁇ L.
  • the concentration of each primer in the primer set is 0.1 to 1.0 ⁇ M.
  • the concentration of the dNTP ranges from 0.1 to 3 mM.
  • the concentration of the ATP is from 1 to 10 mM.
  • the Tris buffer concentration is 20 to 500 mM.
  • the polyethylene glycol has a concentration of from 2.5 to 10 mM.
  • the phosphocreatine concentration is 20 to 100 mM; and the creatine kinase concentration is 10 to 1000 ng/ ⁇ L.
  • the dithiothreitol has a concentration of from 2.5 to 10 mM.
  • a first embodiment of the present invention provides a recombinase polymerase amplification method.
  • the step A0 of extracting a nucleic acid molecule is further included before the reaction system is configured, and the amplification step is as follows:
  • A0 extracting nucleic acid molecules, in this embodiment, extracting human whole blood DNA molecules according to the method of blood genome extraction kit;
  • Adding a magnesium ion preparation to the above reaction system Specifically, in the present embodiment, 5 ⁇ L of a magnesium acetate solution having a concentration of 140 mM is added to the reaction system of the step A, and the mixture is thoroughly mixed and centrifuged.
  • the amplification reaction is carried out at 20 to 65 ° C: in this embodiment, the centrifuge tube is placed in a constant temperature metal bath at 37 ° C for 4 min; the reaction tube is taken out, fully inverted upside down 4-5 times, mixed and centrifuged. Incubate under the same conditions and incubate for 20 min.
  • the present invention also performs PCR amplification on human whole blood DNA molecules, and the amplification steps are as follows:
  • A' extracting human whole blood DNA molecules according to the method of blood genome extraction kit
  • B' in a 200 ⁇ L centrifuge tube, add 1 ⁇ L of human whole blood DNA at a concentration of 9 ⁇ g/ ⁇ L; 5 ⁇ L of 10 ⁇ M upstream primer actinRPA-4_F (SEQ ID NO: 9); 5 ⁇ L of 10 ⁇ M downstream primer actinRPA- 4_R (SEQ ID NO: 10); and 9 ⁇ L of deionized water; 25 ⁇ L of 2 ⁇ Taq mix, mixed and centrifuged;
  • the centrifuge tube is placed in a PCR machine, and the reaction procedure is set: 1 minute at 95 ° C, 30 seconds at 60 ° C, and 30 seconds at 72 ° C for 30 cycles to start the PCR reaction;
  • reaction tube was taken out, sampled and subjected to agarose gel electrophoresis, and the results of the detection are shown in lanes 1 to 4 of Fig. 1.
  • lanes 1-3 are for PCR amplification
  • lane 4 is a negative control for PCR amplification
  • lane 5 is a negative control for recombinase polymerase amplification
  • lanes 6-8 are for recombinase polymerase amplification, 0 A molecular size marker. It can be seen from the experimental results that the recombinase polymerase amplification of this example is comparable to the yield obtained by PCR amplification.
  • the recombinase polymerase amplification method of the present embodiment can effectively amplify the template nucleic acid molecule; however, compared with the conventional PCR technology, the operation is simple, the amplification time is greatly shortened, and the precise temperature instrument can be realized. .
  • a second embodiment of the present invention differs from the first embodiment in that the present embodiment is preceded by an upstream primer actinRPA-0_F (SEQ ID NO: 1) and a downstream primer actin RPA-0_R (SEQ ID NO: 2); Primer actinRPA-1_F (SEQ ID NO: 3) and downstream primer actinRPA-1_R (SEQ ID NO: 4); upstream primer actinRPA-2_F (SEQ ID NO: 5) and downstream primer actin RPA-2_R (SEQ ID NO: 6) The upstream primer actinRPA-3_F (SEQ ID NO: 7) and the downstream primer actinRPA-3_R (SEQ ID NO: 8) were used as primer sets to constitute four reaction systems. Recombinase polymerase amplification of human whole blood DNA. After the end of the amplification reaction, a sample was taken and subjected to a second capillary electrophoresis test, and the results are shown in Fig. 2.
  • lanes 1-3 are the amplification of actin RPA-0 as primers
  • lanes 4-6 are the amplification of actin RPA-01 as primers
  • lanes 7-9 are the amplification of actin RPA-02 as primers.
  • Lanes 10-12 are the amplification of actin RPA-03 as a primer. The results showed that the actin RPA-0, actin RPA-01, actin RPA-02, and actin RPA-03 were all successfully amplified to obtain the desired product.
  • This example demonstrates that the recombinase polymerase amplification method of the present embodiment is capable of efficiently amplifying human whole blood DNA molecules.
  • the amplification step is as follows:
  • A0 extracting nucleic acid molecules, in this embodiment, extracting human whole blood DNA molecules according to the method of blood genome extraction kit;
  • A Three reaction systems including different primer sets were configured: template nucleic acid molecule, primer set, Ecoli RecA protein, lambdaphage Orf protein, Ecoli SSB protein, DNA polymerase, dNTP, ATP and Tris buffer.
  • concentrations of 2 ⁇ premix were prepared: 40 ng/ ⁇ L Ecoli RecA protein, 160 ng/ ⁇ L ⁇ phage Orf protein, 400 ng/ ⁇ L Ecoli SSB protein, 10 ng/ ⁇ L Sau protein, 0.2 mM dNTP, 2 mM ATP, 40 mM Tris buffer, 40 mM phosphocreatine, 20 ng/ ⁇ L creatine kinase, 4% (w/v) polyethylene glycol.
  • the above different primer sets are the upstream primer CFTRRPA-5_F (SEQ ID NO: 11) and the downstream primer CFTRRPA-5_R (SEQ ID NO: 12); the upstream primer CFTRRPA-6_F (SEQ ID NO: 13) and the downstream primer CFTRRPA-6_R. (SEQ ID NO: 14); upstream primer CFTRRPA-7_F (SEQ ID NO: 15) and downstream primer CFTRRPA-7_R (SEQ ID NO: 16).
  • Adding a magnesium ion preparation to the above reaction system Specifically, in the present embodiment, 5 ⁇ L of a 270 mM magnesium chloride solution is added to the reaction system of the step A, and the mixture is thoroughly mixed and centrifuged.
  • the amplification reaction is carried out at 20 to 65 ° C: the centrifuge tube is placed in a constant temperature metal bath at 20 ° C for 4 min; the reaction tube is taken out, fully inverted upside down 4-5 times, mixed and centrifuged, and then the same Conditional incubation, incubation for 20 min.
  • the centrifuge tube was taken out, sampled, and subjected to agarose gel electrophoresis.
  • lane 0 is the molecular size marker
  • lane 1-2 is CFTRRPA-5 as the primer amplification
  • lane 3-4 is CFTRRPA-6 as the primer extension.
  • lanes 5-6 are the amplification of CFTRRPA-7 as a primer.
  • a recombinase polymerase amplification method is provided, and the amplification step is as follows:
  • A0 extracting nucleic acid molecules, in this embodiment, extracting human whole blood DNA according to the method of blood genome extraction kit;
  • the above different primer sets are the upstream primer lambda RPA-8_F (SEQ ID NO: 17) and the downstream primer lambda RPA-8_R (SEQ ID NO: 18); the upstream primer lambda RPA-9_F (SEQ ID NO: 19) and the downstream primer lambda RPA- 9_R (SEQ ID NO: 20); upstream primer lambda RPA-10_F (SEQ ID NO: 21) and downstream primer lambda RPA-10_R (SEQ ID NO: 22); upstream primer lambda RPA-11_F (SEQ ID NO: 23) and downstream primer lambdaRPA-11_R (SEQ ID NO: 24); upstream primer lambda RPA-12_F (SEQ ID NO: 25) and downstream primer lambda RPA-12_R (SEQ ID NO: 26); upstream primer lambda RPA-13_F (SEQ ID NO: 27) and Downstream primer lambdaRPA-13_R (SEQ ID NO: 28).
  • this embodiment adds 5 ⁇ L to the reaction system of step A.
  • a solution of magnesium chloride at a concentration of 45 mM was thoroughly mixed and centrifuged.
  • the amplification reaction is carried out at 20 to 65 ° C: the centrifuge tube is placed in a constant temperature metal bath at 65 ° C for 4 min; the reaction tube is taken out, fully inverted upside down 4-5 times, mixed and centrifuged, and then the same Conditional incubation, incubation for 20 min.
  • the centrifuge tube was taken out, sampled, and subjected to agarose gel electrophoresis.
  • lane 0 is the molecular size marker
  • lane 1-2 is the amplification of lambda RPA-8 as the primer
  • lane 3-4 is the amplification of lambda RPA-9 as the primer.
  • lanes 5-6 are amplification of lambda RPA-10 as primers
  • lanes 7-8 are amplification of lambda RPA-11 as primers
  • lanes 9-10 are amplification of lambda RPA-12 as primers
  • lane 11 -12 is the amplification of lambda RPA-13 as a primer.
  • the results show that the recombinase polymerase amplification method of the present embodiment can effectively amplify human whole blood DNA molecules.
  • the results show that the recombinase polymerase amplification method of the present embodiment can effectively amplify human whole blood DNA molecules.

Abstract

一种重组酶聚合酶扩增试剂盒，包括：Ecoli RecA蛋白；λphage Orf蛋白；Ecoli SSB蛋白及DNA聚合酶；还提供一种重组酶聚合酶扩增方法及扩增试剂。

Description

重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂 技术领域
本发明涉及一种恒温扩增技术，更具体地说，涉及一种重组酶聚合酶扩增(RPA)试剂盒、扩增方法及扩增试剂。
背景技术
传统的体外DNA扩增主要是采用聚合酶链式反应(PCR)的方法，目前已经广泛应用于生物医学等领域。PCR由变性—退火—延伸三个基本反应步骤构成：(1)模板DNA的变性，模板DNA经加热至90-95℃一定时间后，使模板DNA双链或经PCR扩增形成的双链DNA解离，使之成为单链，以便它与引物结合，为下轮反应作准备；(2)模板DNA与引物的退火，模板DNA经加热变性成单链后，温度降至55-60℃，引物与模板DNA单链的互补序列配对结合；(3)引物的延伸，DNA模板—引物结合物在DNA聚合酶的作用下，于70-75℃条件下，以dNTP为反应原料，靶序列为模板，按碱基配对与半保留复制原理，合成一条新的与模板DNA链互补的半保留复制链，重复循环变性—退火—延伸三过程，就可获得更多的“半保留复制链”，而且这种新链又可成为下次循环的模板。每完成一个循环需2-4分钟，2-3小时就能将待扩目的基因扩增放大几百万倍。PCR技术的优点显而易见，但由于其需要精密的温度循环仪器才能完成扩增过程，对仪器的依赖程度较高，加之成本高、反应耗时长，这些局限性使其应用大多限制于条件良好的实验室内，难以广泛应用于现场检测。
因此，需要一种提供不依赖于PCR仪等温度循环仪器的扩增方法。
发明内容
本发明的目的在于提供一种重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂，在恒温条件下实现对特定核酸序列的高效扩增，使得核酸扩增的过程可以直接在无需PCR仪等温度循环仪器的条件下完成。
本发明提供了一种重组酶聚合酶扩增试剂盒，所述试剂盒包括以下组分：Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白及DNA聚合酶。
优选的，所述试剂盒还包括扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液，所述扩增反应缓冲液还包括聚乙二醇、二硫苏糖醇、磷酸肌酸和肌酸激酶中的一种或多种。
优选的，所述试剂盒还包括镁离子制剂。
本发明还提供了一种重组酶聚合酶扩增方法，所述方法包括以下步骤：
A、配置反应体系，所述反应体系包括：模板核酸分子、引物组、Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白、DNA聚合酶、dNTP、ATP及扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液；
B、向所述反应体系中加入镁离子制剂；
C、在20至65℃条件下进行扩增反应。
优选的，所述扩增反应缓冲液还包括聚乙二醇、二硫苏糖醇、磷酸肌酸和肌酸激酶中的一种或多种。
优选的，所述引物组包括一对引物，所述引物的长度为30至65bp。
优选的，所述Ecoli RecA蛋白浓度为20至250ng/μL；所述λphage Orf蛋白浓度为20至80ng/μL；所述Ecoli SSB蛋白的浓度为200至1000ng/μL。
本发明还提供了一种重组酶聚合酶扩增试剂，所述试剂包括：Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白及DNA聚合酶。
优选的，所述扩增试剂还包括扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液；所述扩增反应缓冲液还包括聚乙二醇、二硫苏糖醇、磷酸肌酸和肌酸激酶中的一种或多种。
优选的，所述Ecoli RecA蛋白浓度为20至250ng/μL；所述Ecoli SSB蛋白浓度为200至1000ng/μL；所述λphage Orf蛋白浓度为20至80ng/μL。
本发明的重组酶聚合酶扩增试剂盒，采用Ecoli RecA蛋白、Ecoli SSB蛋白及λphage Orf蛋白协同作用的扩增体系，扩展了重组酶聚合酶扩增的应用范围；与传统PCR技术相比，本发明的重组酶聚合酶扩增反应在恒温条件下即可进行，无需PCR仪等温度循环仪器，不受实验空间限制；本发明的扩增反应在10至60分钟即可完成，远快于PCR技术或其他等温扩增技术。
附图说明
图1是第一具体实施例中重组酶聚合酶扩增及对照PCR扩增的琼脂糖凝胶电泳检测图。
图2是第二具体实施例中重组酶聚合酶扩增的毛细管电泳检测图。
图3是第三具体实施例中重组酶聚合酶扩增的琼脂糖凝胶电泳检测图。
图4是第四具体实施例中重组酶聚合酶扩增的琼脂糖凝胶电泳检测图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合附图及实施例，对本发明进行进一步详细说明。
本发明提出第一实施例，一种重组酶聚合酶扩增试剂盒，包括以下组分：Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白及DNA聚合酶。
需要说明的是，本发明的重组酶聚合酶扩增是基于生物体内同源重组原理的恒温扩增技术：在适宜温度下，重组酶Ecoli RecA蛋白和λphage Orf蛋白共同作用，与引物结合形成酶和引物的复合体，复合体定位到模板核酸分子同源靶序列上并形成链置换；单链结合蛋白与被置换的核苷酸链结合，防止进一步置换；在DNA聚合酶的作用下启动DNA链合成，对模板核酸分子上的目标区域进行扩增。
本发明重组酶聚合酶扩增试剂盒中，所述Ecoli RecA蛋白和Ecoli SSB蛋白来源于大肠杆菌，λphage Orf蛋白来源于λ噬菌体。本发明的λphage Orf蛋白与Ecoli RecA蛋白和Ecoli SSB蛋白的种属来源不同，但可以在同一体系中共同作用并实现重组酶聚合酶扩增，从而大大扩展了重组酶聚合酶扩增技术的应用范围。需要说明的是，本文所称的“来源”仅指其种类，而不是指蛋白的制备来源。
本发明一实施方式中，所述DNA聚合酶优选为在20至65℃条件下有链置换活性的DNA聚合酶。
本发明一实施方式中，所述DNA聚合酶优选为Sau DNA聚合酶、Bsu DNA聚合酶或Bst DNA聚合酶。
本发明一实施方式中，所述试剂盒还包括dNTP，所述dNTP为dTTP、dATP、dGTP和dCTP的等摩尔比混合液；在扩增过程中，所述dNTP用作DNA链合成的底物。
本发明一实施方式中，所述试剂盒还包括ATP；在扩增过程中，所述ATP为模板核酸分子和复合体之间的链置换过程提供能量。
本发明一实施方式中，所述试剂盒还包括扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液；所述Tris缓冲液用于维持反应体系的pH值。
本发明一实施方式中，所述扩增反应缓冲液还包括聚乙二醇；向反应体系中加入聚乙二醇后，聚乙二醇作为高分子物质，占据了反应体系中体积的很大部分，同时排斥其他组分进入此空间，从而使得扩增体系中其他组分更充分地接触，进而提高扩增效率。
本发明一实施方式中，所述聚乙二醇的平均分子量为3000至20000；该分子量范围内的聚乙二醇，对反应体系中其他组分的排斥作用更明显。
本发明一实施方式中，所述扩增反应缓冲液还包括二硫苏糖醇；所述二硫苏糖醇可以有 效防止Ecoli RecA蛋白和DNA聚合酶被氧化。
本发明一实施方式中，所述扩增反应缓冲液还包括磷酸肌酸和肌酸激酶；所述磷酸肌酸和肌酸激酶用于催化ATP再生，这一过程可以不断重复，从而可以保证高效扩增。
需要说明的是，本发明试剂盒中Tris缓冲液、聚乙二醇、二硫苏糖醇、磷酸肌酸和肌酸激酶还可以分开储存，在试剂盒使用时再加以混合。
本发明一实施方式中，所述试剂盒还包括镁离子制剂，所述镁离子制剂用于激活DNA聚合酶，从而缩短反应时间。
需要说明的是，试剂盒中镁离子制剂与其他组分分开储存，试剂盒使用过程中，将试剂盒中其他组分充分混合后，再向其中加入镁离子制剂，能够避免出现非特异性扩增。
本发明一实施方式中，所述镁离子制剂为醋酸镁或氯化镁。
本发明提出了第二实施例，一种重组酶聚合酶扩增方法，包括以下步骤：
A、配置反应体系，所述反应体系包括：模板核酸分子，引物组，Ecoli RecA蛋白，λphage Orf蛋白，Ecoli SSB蛋白，DNA聚合酶，dNTP、ATP及扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液；
B、向所述反应体系中加入镁离子制剂。
C、在20至65℃条件下进行扩增反应。
所述模板核酸分子可以是双链DNA分子、也可以是由RNA反转录合成的cDNA分子。
本发明所述Tris缓冲液用于维持反应体系的pH值，本实施例的pH范围在7.0至8.0。
本发明一实施方式中，所述扩增反应缓冲液还包括聚乙二醇；向反应体系中加入聚乙二醇后，聚乙二醇作为高分子物质，占据了反应体系中体积的很大部分，同时排斥其他组分进入此空间，从而使得扩增体系中其他组分更充分地接触，进而提高扩增效率。
本发明一实施方式中，所述聚乙二醇的平均分子量为3000至20000；该分子量范围内的聚乙二醇，对反应体系中其他组分的排斥作用更明显。
本发明一实施方式中，所述扩增反应缓冲液还包括二硫苏糖醇；所述二硫苏糖醇可以有效防止混合液中的Ecoli RecA蛋白和DNA聚合酶被氧化。
本发明一实施方式中，所述扩增反应缓冲液还包括磷酸肌酸和肌酸激酶；所述磷酸肌酸和肌酸激酶用于催化ATP再生，这一过程可以不断重复，从而可以保证核酸分子的高效扩增。
所述镁离子制剂用于激活DNA聚合酶，从而缩短反应时间，所述反应体系制备完成后再向其中加入镁离子制剂，能够避免出现非特异性扩增。本发明一实施方式中，所述镁离子制剂为醋酸镁或氯化镁。
本发明一实施方式中，所述模板核酸分子为双链DNA分子。
本发明一实施方式中，以人类全血DNA作为模板核酸分子。
本发明一实施方式中，所述引物组包括一对引物；所述引物的长度30至65bp，本方案能够保证链置换过程中识别的特异性。
本发明一实施方式中，分别以actinRPA-0_F(SEQ ID NO:1)、actinRPA-0_R(SEQ ID NO:2)；actinRPA-1_F(SEQ ID NO:3)、actinRPA-1_R(SEQ ID NO:4)；actinRPA-2_F(SEQ ID NO:5)、actinRPA-2_R(SEQ ID NO:6)；或actinRPA-3_F(SEQ ID NO:7)、actinRPA-3_R(SEQ ID NO:8)作为引物组，对所述模板核酸分子进行重组酶聚合酶扩增。
本发明一实施方式中，所述DNA聚合酶为在20至65℃条件下有链置换活性的DNA聚合酶，本方案的DNA聚合酶应用于重组酶聚合酶扩增过程中，使得扩增反应在常温下能够快速进行。
本发明一实施方式中，所述DNA聚合酶为Sau DNA聚合酶、Bsu DNA聚合酶或Bst DNA聚合酶。
本发明一实施方式中，所述模板核酸分子的浓度为10pg/μL至100ng/μL；在本方案的浓度范围内，模板核酸分子的扩增反应能够高效进行。
本发明一实施方式中，所述引物组中每种引物的浓度为0.1至1.0μM；在本方案的浓度范围内，模板核酸分子的扩增反应能够高效进行。
本发明一实施方式中，所述Ecoli RecA蛋白浓度为20至250ng/μL；所述λphage Orf蛋白浓度为20至80ng/μL；所述Ecoli SSB蛋白浓度为200至1000ng/μL；在本方案的浓度范围内，Ecoli RecA蛋白、Ecoli SSB蛋白和λphage Orf蛋白能够更好地发挥协同作用，从而使得扩增效率更高。
本发明一实施方式中，所述DNA聚合酶浓度为5至120ng/μL；在本方案的浓度范围内，模板核酸分子的聚合反应能够高效进行。
本发明一实施方式中，所述dNTP为dTTP、dATP、dGTP和dCTP的等摩尔比混合液；所述dNTP的浓度优选为0.1至3mM；所述dNTP用作聚合反应合成DNA链的底物。
本发明一实施方式中，所述ATP的浓度为1至10mM；在扩增过程中，所述ATP为模板核酸分子和复合体之间的链置换过程提供能量，在本方案的浓度范围内，有利于促进扩增反应的进行。
本发明一实施方式中，所述Tris缓冲液浓度为20至500mM；本方案的pH范围在7.0至8.0；本方案有利于扩增反应的进行。
本发明一实施方式中，所述聚乙二醇的浓度为2.5至10mM；在本方案的浓度范围内，有利 于扩增反应的进行。
本发明一实施方式中，所述磷酸肌酸浓度为20至100mM；所述肌酸激酶浓度为10至1000ng/μL；在本方案的浓度范围内，有利于促进ATP的再生。
本发明一实施方式中，所述二硫苏糖醇的浓度为2.5至10mM；在本方案的浓度范围内，有利于避免Ecoli RecA蛋白和DNA聚合酶被氧化。
优选的，所述镁离子制剂在反应混合液中的浓度为5至30mM；在本方案的浓度范围内，有利于激活DNA聚合酶作用。
本发明提出了第三实施例，一种重组酶聚合酶扩增试剂，包括以下组分：Ecoli RecA蛋白；λphage Orf蛋白；Ecoli SSB蛋白；DNA聚合酶。
本发明一实施方式中，所述试剂还包括dNTP；所述dNTP为dTTP、dATP、dGTP和dCTP的等摩尔比混合液，所述dNTP用作DNA链合成的底物。本发明一实施方式中，所述试剂还包括ATP；所述ATP为模板核酸分子和复合体之间的链置换过程提供能量。
本发明一实施方式中，所述试剂还包括扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液；所述Tris缓冲液用于维持反应体系的pH值，本实施例的pH范围在7.0至8.0。
本发明一实施方式中，所述扩增反应缓冲液还包括磷酸肌酸和肌酸激酶；所述磷酸肌酸和肌酸激酶用于催化ATP再生，这一过程可以不断重复，从而可以保证核酸分子的高效扩增。
本发明一实施方式中，所述扩增反应缓冲液还包括聚乙二醇；向反应体系中加入聚乙二醇后，聚乙二醇作为高分子物质，占据了反应体系中体积的很大部分，同时排斥其他组分进入此空间，从而使得扩增体系中其他组分更充分地接触，进而提高扩增效率。
本发明一实施方式中，所述聚乙二醇的平均分子量为3000至20000；该分子量范围内的聚乙二醇，对反应体系中其他组分的排斥作用更明显。
本发明一实施方式中，所述扩增反应缓冲液还包括二硫苏糖醇；所述二硫苏糖醇可以有效防止Ecoli RecA和DNA聚合酶被氧化。
本发明一实施方式中，所述试剂还包括引物组，所述引物组包括一对引物；所述引物的长度为30至65bp，本方案能够保证链置换过程中识别的特异性。
本发明一实施方式中，所述Ecoli RecA蛋白浓度为20至250ng/μL；所述λphage Orf蛋白浓度为20至80ng/μL；所述Ecoli SSB蛋白浓度为200至1000ng/μL。
本发明一实施方式中，所述DNA聚合酶浓度为5至120ng/μL。
本发明一实施方式中，所述引物组中每种引物的浓度为0.1至1.0μM。
本发明一实施方式中，所述dNTP的浓度范围为0.1至3mM。
本发明一实施方式中，所述ATP的浓度为1至10mM。
本发明一实施方式中，所述Tris缓冲液浓度为20至500mM。
本发明一实施方式中，所述聚乙二醇的浓度为2.5至10mM。
本发明一实施方式中，所述磷酸肌酸浓度为20至100mM；所述肌酸激酶浓度为10至1000ng/μL。
本发明一实施方式中，所述二硫苏糖醇的浓度为2.5至10mM。
以下通过具体实施例对本发明进行进一步的详细说明。
本发明第一具体实施例，提供了一种重组酶聚合酶扩增方法，本实施例在配置反应体系之前还包括提取核酸分子的步骤A0，扩增步骤如下：
A0、提取核酸分子，本实施例按血液基因组提取试剂盒的方法提取人类全血DNA分子；
A、配置反应体系：模板核酸分子、引物组、Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白、DNA聚合酶、dNTP、ATP及Tris缓冲液。具体的，本实施例中配置以下浓度的2×预混液：200ng/μL Ecoli RecA蛋白、50ng/μLλphage Orf蛋白、508ng/μL Ecoli SSB蛋白、160ng/μL Bsu蛋白、5mM ATP、4mM dNTP、100mM Tris缓冲液(pH 7.5)、10mM二硫苏糖醇、100mM磷酸肌酸、200ng/μL肌酸激酶、10.92％(w/v)聚乙二醇。
在200μL离心管中分别加入：1μL浓度为9μg/μL的人类全血DNA；上述引物组：5μL浓度为10μM的上游引物actinRPA-4_F(SEQ ID NO:9)、5μL浓度为10μM的下游引物actinRPA-4_R(SEQ ID NO:10)；25μL 2×预混液；9μL去离子水；混匀并离心。
B、向上述反应体系中加入镁离子制剂：具体的，本实施例中向步骤A的反应体系中加入5μL浓度为140mM的醋酸镁溶液，充分混匀并离心。
C、在20至65℃条件下进行扩增反应：本实施例将离心管置于37℃的恒温金属浴中保温4min；取出反应管，充分地上下颠倒4-5次，混匀并离心，再进行同样条件的孵育，保温20min。
反应结束后，取出离心管，取样并进行琼脂糖凝胶电泳检测，检测结果如图1中5-8泳道所示。
作为对照实验，本发明还对人类全血DNA分子进行了PCR扩增，扩增步骤如下：
A’、按血液基因组提取试剂盒的方法提取人类全血DNA分子；
B’、在200μL离心管中分别加入：1μL浓度为9μg/μL的人类全血DNA；5μL浓度为10μM的上游引物actinRPA-4_F(SEQ ID NO:9)；5μL浓度为10μM的下游引物actinRPA-4_R(SEQ ID NO:10)；和9μL去离子水；25μL 2×Taq mix，混匀并离心；
C’、将离心管置于PCR仪中，设置反应程序：95℃条件下持续1分钟，60℃条件下持续30秒，72℃条件下持续30秒，一共30个循环，开始PCR反应；
反应结束后，取出反应管，取样并进行琼脂糖凝胶电泳检测，检测结果如图1中1-4泳道所示。
图1中泳道1-3为PCR扩增情况，泳道4为PCR扩增的阴性对照，泳道5为重组酶聚合酶扩增的阴性对照，泳道6-8为重组酶聚合酶扩增情况，0为分子大小标记物。从实验结果中可以看出，本实施例的重组酶聚合酶扩增与PCR扩增所获得的产量相差不大。这说明本实施例的重组酶聚合酶扩增方法能够有效对模板核酸分子进行扩增；但与常规PCR技术相比，操作简便，大大缩短了扩增时间，不需要精密的温度仪器即可实现。
本发明第二具体实施例，与第一具体实施例的区别在于，本实施例分别以上游引物actinRPA-0_F(SEQ ID NO:1)和下游引物actinRPA-0_R(SEQ ID NO:2)；上游引物actinRPA-1_F(SEQ ID NO:3)和下游引物actinRPA-1_R(SEQ ID NO:4)；上游引物actinRPA-2_F(SEQ ID NO:5)和下游引物actinRPA-2_R(SEQ ID NO:6)；上游引物actinRPA-3_F(SEQ ID NO:7)和下游引物actinRPA-3_R(SEQ ID NO:8)作为引物组，构成四个反应体系。对人类全血DNA进行重组酶聚合酶扩增。扩增反应结束后取样并进行第二毛细管电泳检测，结果如图2所示。
图2中泳道1-3为actin RPA-0为引物的扩增情况，泳道4-6为actin RPA-01为引物的扩增情况，泳道7-9为actin RPA-02为引物的扩增情况，泳道10-12为actin RPA-03为引物的扩增情况。结果表明，本实施例actin RPA-0、actin RPA-01、actin RPA-02、actin RPA-03均能顺利扩增，获得目的产物。本实施例说明本实施例的重组酶聚合酶扩增方法能够有效对人类全血DNA分子进行扩增。
本发明第三具体实施例，扩增步骤如下：
A0、提取核酸分子，本实施例按血液基因组提取试剂盒的方法提取人类全血DNA分子；
A、配置三个包括不同引物组的反应体系：模板核酸分子、引物组、Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白、DNA聚合酶、dNTP、ATP及Tris缓冲液。具体的，本实施例中配置以下浓度的2×预混液：40ng/μL Ecoli RecA蛋白、160ng/μLλphage Orf蛋白、400ng/μL Ecoli SSB蛋白、10ng/μL Sau蛋白、0.2mM dNTP、2mM ATP、40mM Tris缓冲液、40mM磷酸肌酸、20ng/μL肌酸激酶、4％(w/v)聚乙二醇。
在200μL离心管中分别加入：1μL浓度为0.45pg/μL的人类全血DNA；上述不同引物组：5μL浓度为0.9μM的上游引物、5μL浓度为0.9μM的下游引物；25μL 2×预混液；9μL去离子水，混匀并离心；
上述不同引物组分别为上游引物CFTRRPA-5_F(SEQ ID NO:11)和下游引物CFTRRPA-5_R(SEQ ID NO:12)；上游引物CFTRRPA-6_F(SEQ ID NO:13)和下游引物CFTRRPA-6_R(SEQ ID NO:14)；上游引物CFTRRPA-7_F(SEQ ID NO:15)和下游引物CFTRRPA-7_R(SEQ ID NO:16)。
B、向上述反应体系中加入镁离子制剂：具体的，本实施例中向步骤A的反应体系中加入5μL浓度为270mM的氯化镁溶液，充分混匀并离心。
C、在20至65℃条件下进行扩增反应：将离心管置于20℃的恒温金属浴中保温4min；取出反应管，充分地上下颠倒4-5次，混匀并离心，再进行同样条件的孵育，保温20min。
反应结束后，取出离心管，取样并进行琼脂糖凝胶电泳检测。
琼脂糖凝胶电泳检测如图3所示，图3中泳道0为分子大小标记物，泳道1-2为CFTRRPA-5为引物的扩增情况，泳道3-4为CFTRRPA-6为引物的扩增情况，泳道5-6为CFTRRPA-7为引物的扩增情况。结果表明，本实施例的重组酶聚合酶扩增方法能够有效对人类全血DNA分子进行扩增。
本发明第四具体实施例，提供了一种重组酶聚合酶扩增方法，扩增步骤如下：
A0、提取核酸分子，本实施例按血液基因组提取试剂盒的方法提取人类全血DNA；
A、配置六个包括不同引物组的反应体系：模板核酸分子、引物组、Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白、DNA聚合酶、dNTP、ATP及Tris缓冲液。具体的，本实施例中配置以下浓度的2×预混液：500ng/μL Ecoli RecA蛋白；40ng/μLλphage Orf蛋白；2000ng/μL Ecoli SSB蛋白；240ng/μL Bst蛋白；6mM dNTP；20mM ATP；1000mM Tris缓冲液；40mM磷酸肌酸；2000ng/μL肌酸激酶；20％(w/v)聚乙二醇。
在200μL离心管中分别加入：1μL浓度为4.5mg/μL的人类全血DNA；上述不同引物组：5μL浓度为0.9μM的上游引物、5μL浓度为0.9μM的下游引物；25μL 2×预混液；9μL去离子水，混匀并离心。
其中上述不同引物组分别为上游引物lambdaRPA-8_F(SEQ ID NO:17)和下游引物lambdaRPA-8_R(SEQ ID NO:18)；上游引物lambdaRPA-9_F(SEQ ID NO:19)和下游引物lambdaRPA-9_R(SEQ ID NO:20)；上游引物lambdaRPA-10_F(SEQ ID NO:21)和下游引物lambdaRPA-10_R(SEQ ID NO:22)；上游引物lambdaRPA-11_F(SEQ ID NO:23)和下游引物lambdaRPA-11_R(SEQ ID NO:24)；上游引物lambdaRPA-12_F(SEQ ID NO:25)和下游引物lambdaRPA-12_R(SEQ ID NO:26)；上游引物lambdaRPA-13_F(SEQ ID NO:27)和下游引物lambdaRPA-13_R(SEQ ID NO:28)。
B、向上述反应体系中加入镁离子制剂：具体的，本实施例向步骤A的反应体系中加入5μL 浓度为45mM的氯化镁溶液，充分混匀并离心。
C、在20至65℃条件下进行扩增反应：将离心管置于65℃的恒温金属浴中保温4min；取出反应管，充分地上下颠倒4-5次，混匀并离心，再进行同样条件的孵育，保温20min。
反应结束后，取出离心管，取样并进行琼脂糖凝胶电泳检测。
琼脂糖凝胶电泳检测如图4所示，图4中泳道0为分子大小标记物，泳道1-2为lambdaRPA-8为引物的扩增情况，泳道3-4为lambdaRPA-9为引物的扩增情况，泳道5-6为lambdaRPA-10为引物的扩增情况，泳道7-8为lambdaRPA-11为引物的扩增情况，泳道9-10为lambdaRPA-12为引物的扩增情况，泳道11-12为lambdaRPA-13为引物的扩增情况。结果表明，本实施例的重组酶聚合酶扩增方法能够有效对人类全血DNA分子进行扩增。
结果表明本实施例的重组酶聚合酶扩增方法能够有效对人类全血DNA分子进行扩增。
以上所述仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明的保护范围之内。

Claims (10)

  1. 一种重组酶聚合酶扩增试剂盒，其特征在于，所述试剂盒包括以下组分：Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白及DNA聚合酶。
  2. 根据权利要求1所述的重组酶聚合酶扩增试剂盒，其特征在于，所述试剂盒还包括扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液，所述扩增反应缓冲液还包括聚乙二醇、二硫苏糖醇、磷酸肌酸和肌酸激酶中的一种或多种。
  3. 根据权利要求2所述的重组酶聚合酶扩增试剂盒，其特征在于，所述试剂盒还包括镁离子制剂。
  4. 一种重组酶聚合酶扩增方法，其特征在于，所述方法包括以下步骤：
    A、配置反应体系，所述反应体系包括：模板核酸分子、引物组、Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白、DNA聚合酶、dNTP、ATP及扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液；
    B、向所述反应体系中加入镁离子制剂；
    C、在20至65℃条件下进行扩增反应。
  5. 根据权利要求4所述的重组酶聚合酶扩增方法，其特征在于，所述扩增反应缓冲液还包括聚乙二醇、二硫苏糖醇、磷酸肌酸和肌酸激酶中的一种或多种。
  6. 根据权利要求4所述的重组酶聚合酶扩增方法，其特征在于，所述引物组包括一对引物，所述引物的长度为30至65bp。
  7. 根据权利要求4所述的重组酶聚合酶扩增方法，其特征在于，所述Ecoli RecA蛋白浓度为20至250ng/μL；所述λphage Orf蛋白浓度为20至80ng/μL；所述Ecoli SSB蛋白浓度为200至1000ng/μL。
  8. 一种重组酶聚合酶扩增试剂，其特征在于，所述试剂包括：Ecoli RecA蛋白、λphage Orf蛋白、Ecoli SSB蛋白及DNA聚合酶。
  9. 根据权利要求8所述的重组酶聚合酶扩增试剂，其特征在于，所述扩增试剂还包括扩增反应缓冲液，所述扩增反应缓冲液包括Tris缓冲液；所述扩增反应缓冲液还包括聚乙二醇、二硫苏糖醇、磷酸肌酸和肌酸激酶中的一种或多种。
  10. 根据权利要求8所述的重组酶聚合酶扩增试剂，其特征在于，所述Ecoli RecA蛋白浓度为20至250ng/μL；所述Ecoli SSB蛋白的浓度为200至1000ng/μL；所述λphage Orf蛋白浓度为20至80ng/μL。
PCT/CN2017/093088 2016-07-22 2017-07-17 重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂 WO2018014799A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610587482.4 2016-07-22
CN201610587482.4A CN107641635A (zh) 2016-07-22 2016-07-22 重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂

Publications (1)

Publication Number Publication Date
WO2018014799A1 true WO2018014799A1 (zh) 2018-01-25

Family

ID=60991968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/093088 WO2018014799A1 (zh) 2016-07-22 2017-07-17 重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂

Country Status (2)

Country Link
CN (1) CN107641635A (zh)
WO (1) WO2018014799A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115948515A (zh) * 2022-12-30 2023-04-11 圣湘生物科技股份有限公司 重组酶介导的全冻干恒温扩增体系及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123825A1 (en) * 2018-12-20 2020-06-25 Alveo Technologies, Inc. Isothermal amplification with electrical detection
CN111154739B (zh) * 2020-02-06 2021-03-02 广州普世利华科技有限公司 一种新型重组酶依赖型扩增方法及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035205A2 (en) * 2006-05-04 2008-03-27 Asm Scientific, Inc. Recombinase polymerase amplification
CN104694662A (zh) * 2015-04-03 2015-06-10 杜文红 核酸等温扩增反应检测方法及应用该方法的检测试剂盒
CN105567866A (zh) * 2016-03-25 2016-05-11 苏州达麦迪生物医学科技有限公司 用于耐甲氧西林金黄色葡萄球菌检测的引物、试剂盒及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118917A1 (en) * 2006-11-21 2008-05-22 Applera Corporation Isothermal SNP Detection Method
CN104818263A (zh) * 2015-05-07 2015-08-05 浙江泰晶生物科技有限公司 用于常温等温核酸大片段体外扩增的蛋白酶及扩增方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035205A2 (en) * 2006-05-04 2008-03-27 Asm Scientific, Inc. Recombinase polymerase amplification
CN104694662A (zh) * 2015-04-03 2015-06-10 杜文红 核酸等温扩增反应检测方法及应用该方法的检测试剂盒
CN105567866A (zh) * 2016-03-25 2016-05-11 苏州达麦迪生物医学科技有限公司 用于耐甲氧西林金黄色葡萄球菌检测的引物、试剂盒及方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CURTIS, F. A.: "Phage Orf Family Recombinases: Conservation of Activities and Involvement of the Central Channel in DNA Binding", PLOS ONE, vol. 9, no. 8, 1 August 2014 (2014-08-01) *
CURTIS, F. A.: "The C-terminus of the phage X Orf recombinase is involved in DNA binding", JOURNAL OF MOLECULAR RECOGNITION, vol. 24, 13 December 2010 (2010-12-13) *
GAO, WEIFANG ET AL.: "Recombinase Polymerase Amplification: A New DNA/RNA Amplification Strategy", CHINESE JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 32, no. 6, 30 June 2016 (2016-06-30), pages 627 - 634 *
JING, ZHIGANG ET AL.: "Research Progress on Recombinase Polymerase Amplification", BIOTECHNOLOGY BULLETIN, vol. 32, no. 6, 26 June 2016 (2016-06-26), pages 47 - 53 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115948515A (zh) * 2022-12-30 2023-04-11 圣湘生物科技股份有限公司 重组酶介导的全冻干恒温扩增体系及其制备方法和应用

Also Published As

Publication number Publication date
CN107641635A (zh) 2018-01-30

Similar Documents

Publication Publication Date Title
EP3470529B1 (en) Nucleic acid isothermal self-amplification method
AU2013337280B2 (en) Barcoding nucleic acids
US9012183B2 (en) Use of template switching for DNA synthesis
US20070117121A1 (en) cDNA library preparation
US20070128649A1 (en) Synthesis of error-minimized nucleic acid molecules
US20100035238A1 (en) Anti-freeze protein enhanced nucleic acid amplification
WO2018014799A1 (zh) 重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂
CN105452480B (zh) 经由剪刀状结构的dna扩增(dasl)
MX2022005328A (es) Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
US20210310048A1 (en) Method for generating single-stranded circular dna libraries for single molecule sequencing
AU2015311099A2 (en) Preparation of adapter-ligated amplicons
JP2014525753A (ja) アニオン性ポリマーを含む、ｒｔ−ｐｃｒ用組成物及び方法
WO2016090344A1 (en) Amplification of nucleic acids
CN107488655B (zh) 测序文库构建中5’和3’接头连接副产物的去除方法
KR20120097214A (ko) 핵산 증폭 과정에 있어서 단일 가닥 결합 단백질의 용도
CN116497093A (zh) 一种高效恒温扩增方法
CN102703400A (zh) 热启动dna聚合酶及其应用
CN106701738B (zh) 一种等温解开双链dna及制备单链dna的方法
He et al. Nickase-dependent isothermal DNA amplification
JP2017534297A (ja) トランスポゼースによる核酸の切断及びリンカー付加の方法及び試薬
US20160355870A1 (en) Generation of ligation-ready dna amplicons
CN110551794B (zh) 对rna分子进行处理的方法及试剂盒和复合体
JP6416885B2 (ja) 高温で活性なｈｉｖタイプ１グループｏ逆転写酵素
CN107312788A (zh) 一种tale重复序列载体的构建方法
JP2023071073A (ja) 鋳型ｄｎａの製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17830433

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/06/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17830433

Country of ref document: EP

Kind code of ref document: A1